| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000022109 |
| Receipt No. | R000025487 |
| Official scientific title of the study | Effect of Empagliflozin on Ambulatory Blood Pressure Monitoring (ABPM) |
| Date of disclosure of the study information | 2018/05/01 |
| Last modified on | 2016/04/27 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | Effect of Empagliflozin on Ambulatory Blood Pressure Monitoring (ABPM) | |
| Title of the study (Brief title) | Effect of Empagliflozin on ABPM | |
| Region |
|
|
| Condition | ||
| Condition | Diabetics Mellitus
Hypertension |
|
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To investigate the effect of Empagliflozin on 24 hour blood pressure changes by using ABPM |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Change of 24 hour blood pressure |
| Key secondary outcomes | Changes of fast blood glucose and HbA1c
Change of renal function |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Cluster |
| Blinding | Open -no one is blinded |
| Control | Placebo |
| Stratification | YES |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | Numbered container method |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Empagliflozin | |
| Interventions/Control_2 | DPP4 Inhibitor | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients with DM and Hypertension | |||
| Key exclusion criteria | eGFR<30ml/min/1.73m2
Liver Dysfunction |
|||
| Target sample size | 20 | |||
| Research contact person | |
| Name of lead principal investigator | Hidetomo Nakamoto |
| Organization | Saitama Medical University |
| Division name | Department of General Internal Medicine |
| Address | 38 Morohongo, Moroyama-machi, Iruma-gun, Saitama |
| TEL | 049-276-1667 |
| nakamo_h@saitama-med.ac.jp | |
| Public contact | |
| Name of contact person | Hidetomo Nakamoto |
| Organization | Saitama Medical University |
| Division name | Department of General Internal Medicine |
| Address | 38 Morohongo, Moroyama-machi, Iruma-gun, Saitama |
| TEL | 049-276-1667 |
| Homepage URL | |
| nakamo_h@saitama-med.ac.jp | |
| Sponsor | |
| Institute | Department of General Internal Medicine, Saitama Medical University |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | Department of Internal Medicine, Saitama Medical University |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 埼玉医科大学病院 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025487 |